Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Alzheimer's Disease Therapeutics Market To 2019Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
By: Reportstack Despite a number of recent high-profile failures, there is still great interest surrounding AD, with 254 medicines in the discovery and preclinical stages alone. However, the number of therapies in later stages of the pipeline is somewhat limited, with a reasonable 68 molecules in Phase II, but only five in Phase III. Dr. Waldemar Ockert, Managing Analyst at GBI Research, says: “This reflects an endemic problem in AD therapeutics, as the progression rate from Phase II to Phase III, and then to filing for marketing approval after Phase III studies, is among the lowest across the entire pharmaceutical industry. “The lack of strong potential disease-modifying therapies in the pipeline that could have a substantial impact on the market is particularly troubling, as the overall global prevalence of the disease is forecast to increase.” Another market restraint is the fact that many drgs are tested in patients with established AD and advanced neurodegeneration. “Most trials test products in patients with mild to moderate AD, at which stage neurodegeneration is likely to be too advanced for a potentially disease-modifying therapeutic intervention. The fact that a reasonably high proportion of patients will not respond to therapy increases the overall possibility of the durg not attaining statistical significance,” There is a severe need for definitive biomarkers, particularly for diagnosis of asymptomatic and prodromal AD, a greater understanding of the disease etiology and further research into an earlier therapeutic intervention, with amyloid beta targeting agents and other potentially disease-modifying therapeutics. The table of contents and more details about this report can be found by visiting http://www.reportstack.com/ Other Reports from Reportstack: Monoclonal Antibodies Market in Breast Cancer to 2019 (http://www.reportstack.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|